Generalizability of HFrEF trials 45 a. Threshold are reversed when moved from exclusion to inclusion criteria to standardise across trials Supplementary table 1 (continued). Characteristics, inclusion and exclusion criteria of trials Study name BEAUTIFUL CONFIRM-HF FAIR-HF PANTHEON SHIFT Participation in a drug or device trial within the previous 30 days. Subject currently is enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study, or subject is receiving other investigational agent(s). Exercise training program(s) in the 3 months prior to screening or planned in the next 6 months. Participation in another clinical trial within previous 30 days and/or anticipated participation in another trial during this study. Use of other investigational drugs. Previous (within 30 days or 5 half-lives of the investigational drug, whichever is longer) or concomitant participation in another clinical study with investigational medicinal product(s) or device(s) Participation in another drug or device trial at the same time or within 5 drug half-lives of the investigational drug, or within the time legally required by regulatory authorities, whichever are longer) or already enrolled in the study Oral iron therapy at doses >100 mg/day in previous 1 week prior to randomization. Known hypersensitivity to ivabradine Subject has known sensitivity to any of the products to be administered during dosing. Known hypersensitivity to Ferinject®. Known allergies or hypersensitivities to adhesives or hydrogel Known hypersensitivity to ivabradine Known hereditary problems of galactose intolerance, Lapp lactase deficiency or glucosegalactose malabsorption Known hereditary problems of lactose intolerance, galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption 2.1
RkJQdWJsaXNoZXIy MjY0ODMw